[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338081-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-338081-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","unbiased-discovery-of-cancer-pathways-and-therapeutics-using-pathway-ensemble-tooland-benchmark","Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tooland Benchmark","","Accurately identifying perturbed biological pathways is fundamental for understanding disease mechanisms and developing therapeutic strategies. The work evaluates whether existing pathway analysis tools enable unbiased discovery and finds that most perform sub-optimally. It introduces Benchmark for critical evaluation and the Pathway Ensemble Tool (PET), which outperforms prior methods. Using PET, prognostic pathways across 12 cancer types are identified, with pathway genes functioning as reliable biomarkers. Normalization of pathways via drug repurposing yields therapeutic opportunities, including an example drug prediction for bladder cancer.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unbiased-discovery-of-cancer-pathways-and-therapeutics-using-pathway-ensemble-tooland-benchmark/338081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unbiased-discovery-of-cancer-pathways-and-therapeutics-using-pathway-ensemble-tooland-benchmark/338081.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What experimental example is mentioned regarding drug repurposing?","Question",{"text":63,"@type":64},"For bladder cancer, the top predicted repurposed drug (aCDK2/9 inhibitor) represses cell growth in vitro and in vivo.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},338081,1791118890,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,97,102,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},"Technology",50,"technology",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":99,"show_sort_weight":100,"slug":101},7,"Healthcare",40,"healthcare",{"id":103,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},8,30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":103,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":100,"preview_page_count":33,"preview_urls":137},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-024-51859-9](https://doi.org/10.1038/s41467-024-51859-9)  \nUnbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tooland Benchmark  \nReceived: 6 March 2023  \n\n| Accepted: 19 August 2024 |\n| --- |\n| |\n| Check for updates |\n\nLuopin Wang1,2,11, Aryamav Pattnaik2,3,11, Subhransu Sekhar Sahoo2,3,  \nElla G. Stone2,4, Yuxin Zhuang2,3, Annaleigh Benton2,4, Md Tajmul3,5,  \nSrishti Chakravorty2,3, Deepika Dhawan6, My An Nguyen2,7, Isabella Sirit2,4, Kyle Mundy7, Christopher J. Ricketts 8, Marco Hadisurya 2,3, GarimaBaral 2,4, Samantha L. Tinsley2,4, Nicole L. Anderson2,4, Smriti Hoda3, Scott D. Briggs 2,3, Hristos Z. Kaimakliotis9, Brittany L. Allen-Petersen2,4, W. Andy Tao 2,3,10,  \nW. Marston Linehan 8, Deborah W. Knapp2,6, Jason A. Hanna 2,4,  \nMatthew R. Olson2,4, Behdad Afzali5,12  & Majid Kazemian 1,2,3,12   \nCorrectly identifying perturbed biological pathways is a critical step in uncovering basic disease mechanisms and developing much-needed therapeutic strategies. However, whether current tools are optimal for unbiased discovery of relevant pathways remains unclear. Here, we create “Benchmark” to critically evaluate existing tools and ﬁnd that most function sub-optimally. We thus develop the “Pathway Ensemble Tool”(PET), which outperforms existing methods. Deploying PET, we identify prognostic pathways across 12 cancer types. PET-identiﬁed prognostic pathways offer additional insights, with genes within these pathways serving as reliable biomarkers for clinical outcomes. Additionally, normalizing these pathways using drug repurposing strategies represents therapeutic opportunities. For example, the top predicted repurposed drug for bladder cancer, aCDK2/9inhibitor, represses cell growth in vitro and in vivo. We anticipate that using Benchmark and PET for unbiased pathway discovery will offer additional insights into disease mechanisms across a spectrum of diseases, enabling biomarker discovery and therapeutic strategies.  \nThe pathogenesis of complex diseases is often underpinned by dysregulation of several cellular pathways. This is well exempliﬁed by neoplastic diseases, where abnormalities in multiple pathways contribute to cancerous transformation or in which cancer-disposing  \nevents perturb multiple cellular pathways. Despite notable successes in some cancers, limited therapeutic gains have been made by identiﬁcation and targeting of single contributory genes. Precisely pinpointing key dysregulated celluar pathways in cancer and ranking  \n1Department of Computer Science, Purdue University, West Lafayette, IN, USA. 2Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA. 3Department of Biochemistry, Purdue University, West Lafayette, IN, USA. 4Department of Biological Sciences, Purdue University, West Lafayette, IN, USA. 5Immunoregulation Section, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA. 6Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA. 7Department of Biomedical Engineering, Purdue University, West Lafayette, IN, USA. 8Urologic Oncology Branch of Center for Cancer Research, National Cancer Institute (NCI), NIH, Bethesda, MD, USA. 9Department of Urology, School of medicine, Indiana University, Indianapolis, IN, USA. 10Department of Chemistry, Purdue University, West Lafayette, IN, USA. 11These authors contributed equally: Luopin Wang, Aryamav Pattnaik 14These authors jointly supervised this work: Behdad Afzali, Majid Kazemian  \ne-mail: [ben.afzali@nih.gov](ben.afzali@nih.gov); [kazemian@purdue.edu](kazemian@purdue.edu)  \nthem by order of importance is, therefore, of major biological and clinical signiﬁcance. Doing so would enable molecular subtyping, determination of diagnostic/prognostic biomarkers and inform choice of effective and cancer-speciﬁc drug regimens. This is especially important at the present tim","cbCainhD5fj0TVdy","https://ap.wps.com/l/cbCainhD5fj0TVdy","pdf",2367686,16,"English","# Introduction\n## Need for unbiased pathway discovery\n# Benchmarking of existing pathway tools\n# Pathway Ensemble Tool (PET)\n## Prognostic pathway identification across cancer types\n## Biomarkers and clinical outcome relevance\n# Therapeutic opportunities via drug repurposing\n# Conclusion and expected impact","[{\"question\":\"What experimental example is mentioned regarding drug repurposing?\",\"answer\":\"For bladder cancer, the top predicted repurposed drug (aCDK2/9 inhibitor) represses cell growth in vitro and in vivo.\"}]","Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tooland Benchmark | PDF",1790021883,[138,142,146,150],{"page_no":22,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dbe40f9e55d3fb9ff0fe935b079da5d.webp",983,1305,{"page_no":26,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a2937e0af77fb76383fcb67dd3293d6.webp",982,1304,{"page_no":30,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef8c2b8b253d4977c1a2f743506c2d16.webp",981,1303,{"page_no":33,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c913a70ca6a5a6d0afc89a02e3c3eaf4.webp",980,1301]